Assessment of Prevalence and Risk   Factors of Chronic Kidney Disease in a Tertiary Care Teaching Hospital

Swapna B; Nousheen Nabeela; Tanusha Tanusha; Firdouse Amena; Sowmya P

doi:10.37022/wjcmpr.v8i2.395

Authors

B. Swapna Assistant Professor, Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Nabeela Nousheen Pharm. D Intern, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Tanusha Pharm. D Intern, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
Amena Firdouse Pharm. D Intern, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.
P.Sowmya Pharm. D Intern, Smt. Sarojini Ramulamma College of Pharmacy, (Palamuru University), Seshadri Nagar, Mahabubnagar District, Telangana State, India.

Abstract

Chronic Kidney Disease is a long-term and irreversible condition in which the kidneys progressively lose their ability to filter waste materials and regulate fluid and electrolyte levels in the body. This has become a significant global health issue due to its rising prevalence and its connection with non-communicable diseases such as Type 2 Diabetes and Hypertension. CKD greatly elevates the risk of cardiovascular diseases, end-stage renal failure, and early death, placing a significant strain on healthcare systems, especially in low- and middle-income nations.In tertiary care hospitals, many patients are diagnosed at advanced stages of CKD, as early stages typically show no symptoms and public awareness of the disease remains low. Late diagnosis and limited access to routine screenings further aggravate disease outcomes. Analyzing the prevalence and risk factors of CKD in tertiary care settings helps pinpoint high-risk groups, prevalent contributing factors, and shortcomings in early detection and prevention efforts. These studies can enhance patient awareness, encourage early diagnosis, and assist in adopting better management practices to lower complications and boost quality of life for CKD patients.

Keywords:

Chronic Kidney Disease, CKD prevalence, Risk factors, Diabetes mellitus, Hypertension, Cardiovascular disease, eGFR, End-stage renal disease, Hospital-based observational study

DOI

https://doi.org/10.37022/wjcmpr.v8i2.395

References

1. Herrington WG, Staplin N, Wanner C. Chronic kidney disease. Lancet. 2026;407(10523):90-104.

2. Kumar NA, Konakanchi VB, Veliyambra A, Gundraju S, Kadari S, Murukuti VK, Thondur SM, Kande A, Konakanchi V, Thonduru SM. Knowledge, Attitude, and Screening of Kidney Disease Among Asymptomatic Healthcare Students at a Tertiary Healthcare Center in Coastal Andhra Pradesh. Cureus. 2025 Aug 17;17(8):e90299.

3. Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C. Chronic kidney disease and the global public health agenda: an international consensus. Nature Reviews Nephrology. 2024 Jul;20(7):473-85.

4. Stevens PE, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;106(Suppl 1):S1-S150.

5. Kovesdy CP. Epidemiology of chronic kidney disease: an update. Kidney Int Suppl (2011). 2022;12(1):7-11.

6. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.

7. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120-131.

8. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51(6):957-972.

9. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316(6):602-610.

10. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.

11. Fogo AB. Approach to renal biopsy. Am J Kidney Dis. 2015;66(6):1001-1018.

12. Greenwood SA, Koufaki P, Mercer TH, MacLaughlin HL, Rush R, Lindup H, et al. Effect of exercise training on CKD. Nat Rev Nephrol. 2015;11(12):738-748.

13. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-2883.

14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150.

15. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the KDIGO 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-830.

16. McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Am J Kidney Dis. 2013;61(6):930-940.

17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29.

18. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of chronic kidney disease. J Am Soc Nephrol. 2012;23(12):1927-1935.

19. Babitt JL, Lin HY. Mechanisms of anemia in CKD. Nat Rev Nephrol. 2012;8(11):646-658.

20. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality. Lancet. 2010;375(9731):2073-2081.

21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.

22. Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2009;(3):CD001892.

23. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-1539.

24. Orth SR, Hallan SI. Smoking: a risk factor in the progression of chronic kidney disease and cardiovascular morbidity. Kidney Int. 2008;73(9):956-961.

25. Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007;357(13):1316-1325.

26. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from KDIGO. Kidney Int. 2006;69(11):1945-1953.

27. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from KDIGO. Am J Kidney Dis. 2005;45(2):212-221.

28. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.

29. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18.